Related Experiment Videos
Unfractionated and low-molecular-weight heparins in acute coronary syndromes: current recommendations
1Department of Cardiology, Cleveland Clinic, USA.
Cleveland Clinic Journal of Medicine
|January 25, 2000
Insights
Heparin therapy is recommended for acute coronary syndromes, excluding patients with bleeding or stroke. This review covers heparin pharmacology, clinical trials, and usage guidelines for unfractionated and low-molecular-weight heparins.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute coronary syndromes (ACS) require prompt management.
- Heparin is a key anticoagulant in cardiovascular medicine.
Purpose of the Study:
- To review the role of unfractionated and low-molecular-weight heparins in ACS.
- To provide evidence-based recommendations for heparin use in ACS patients.
Main Methods:
- Literature review of heparin pharmacology.
- Analysis of clinical trials involving heparin in ACS.
- Synthesis of current guidelines for heparin therapy.
Main Results:
- Unfractionated heparin (UFH) and low-molecular-weight heparins (LMWH) are effective anticoagulants for ACS.
- Heparin therapy is indicated for ACS patients without contraindications like bleeding or stroke.
- Specific recommendations for UFH and LMWH selection and dosing are discussed.
Conclusions:
- Heparin is a critical component of ACS management.
- Appropriate selection and administration of UFH and LMWH optimize patient outcomes.
- Guidelines support the use of heparin in ACS patients lacking contraindications.
Abstract:
All patients with acute coronary syndromes and without obvious bleeding or acute cerebrovascular events are candidates for heparin therapy. This article is a review of the pharmacology of unfractionated and low-molecular-weight heparins, trials of heparin therapy in acute coronary syndromes, and recommendations for using these agents.